ArriVent BioPharma (AVBP) Stock Chart & Stock Price History $20.33 +0.16 (+0.79%) As of 04:00 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ArriVent BioPharma Stock Price Performance The ArriVent BioPharma (AVBP) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 8.95%, with a year-to-date return of -23.69%. In the past month, the stock has decreased 13.56%, reflecting recent market activity. As of the latest close, ArriVent BioPharma traded at $20.17 with a market cap of $690.02 million and volume of 341,967 shares. Receive AVBP Stock News and Ratings via EmailSign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-2.05%1 Month Performance-13.56%3 Month Performance+24.72%Year-To-Date Performance-23.69%1 Year Performance+8.95% AVBP Stock Chart for Tuesday, July, 8, 2025 AVBP Chart by TradingView ArriVent BioPharma Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/07/2025$20.76$20.17-2.82%$20.79$19.71341,967 shs$690.02 million07/04/2025$20.76$20.76$21.20$20.01286,026 shs$710.09 million07/03/2025$21.10$20.76-1.64%$21.20$20.01286,026 shs$710.03 million07/02/2025$20.89$21.10+1.01%$21.89$20.00949,102 shs$721.83 million07/01/2025$21.77$20.89-4.04%$22.07$20.68415,115 shs$714.65 million06/30/2025$22.91$21.77-4.98%$23.17$21.68297,630 shs$744.75 million06/27/2025$22.81$22.91+0.44%$23.26$22.31876,062 shs$783.75 million06/26/2025$22.80$22.81+0.04%$23.05$22.12284,039 shs$780.33 million06/25/2025$23.11$22.80-1.34%$23.44$22.53418,097 shs$780.06 million06/24/2025$22.80$23.11+1.36%$24.03$22.71928,851 shs$790.59 million Get the Latest News and Ratings for AVBP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. 06/23/2025$25.22$22.80-9.60%$25.73$22.041.35 million shs$779.99 million06/20/2025$24.89$25.22+1.33%$25.58$24.55441,501 shs$862.85 million06/19/2025$24.89$24.89$25.63$24.61221,896 shs$851.49 million06/18/2025$24.98$24.89-0.36%$25.63$24.61221,896 shs$851.49 million06/17/2025$25.42$24.98-1.73%$25.80$24.06347,325 shs$854.64 million06/16/2025$23.27$25.42+9.24%$25.57$22.97512,100 shs$869.69 million06/13/2025$23.63$23.27-1.52%$23.93$22.92441,320 shs$796.14 million06/12/2025$23.28$23.63+1.50%$23.64$22.65672,635 shs$808.45 million06/11/2025$24.50$23.28-4.98%$25.07$23.20179,002 shs$796.48 million06/10/2025$23.60$24.50+3.81%$24.75$23.76322,545 shs$838.22 million06/09/2025$23.52$23.60+0.34%$24.05$23.20199,839 shs$807.43 million Related Companies MorphoSys Stock Chart Immunovant Stock Chart Alvotech Stock Chart Crinetics Pharmaceuticals Stock Chart Organon & Co. Stock Chart HUTCHMED Stock Chart Catalyst Pharmaceuticals Stock Chart Amneal Pharmaceuticals Stock Chart Bausch Health Cos Stock Chart Mirum Pharmaceuticals Stock Chart Receive AVBP Stock News and Ratings via EmailSign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:AVBP) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
